Summary
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
History
Vir Biotechnology was founded in 2016 by President and CEO Dr. George Scangos and Chief Scientific Officer Peter Thompson. Together they bring decades of experience in biotechnology drug discovery, development and commercialization. Expressing their deep conviction in the power of monoclonal antibodies to cure disease, George and Peter have driven Vir since day one. Over the past four years, Vir has assembled world-class scientific and commercial leadership, raised over $530M in venture capital, established strategic collaborations and partnerships, built state-of-the-art facilities and developed a promising pipeline of product candidates for large unmet medical needs.
Mission
At Vir, we believe that immunology holds the greatest promise to revolutionize the treatment of complex and serious infectious diseases. We strive to make an impactful difference in the lives of patients by bringing together the most innovative science with the highest standards for safety, effectiveness, and availability.
Vision
To become the leading research-driven, discovery- fueled, pioneering organization in the development of immunology-based treatments and breakthrough medicines.
Key Team
Dr. Phillip Pang M.D., Ph.D. (Exec. VP, Chief Medical Officer & Interim Head of Research)
Dr. Klaus Frueh Ph.D. (Co-Founder & Scientific Advisor)
Dr. Lawrence Corey M.D. (Co-Founder & Scientific Advisor)
Dr. Louis J. Picker M.D. (Co-Founder & Scientific Advisor)
Ms. Johanna Friedl-Naderer (Exec. VP & COO)
Mr. Steven J. Rice (Exec. VP & Chief Admin. Officer)
Ms. Heather Rowe Armstrong (VP of Investor Relations)
Recognition and Awards
Vir Biotechnology has been recognized by multiple organizations and publications. In 2017, the company was named a CB Insights AI 100 Company, TechCrunch Disrupt Battlefield participant, and a Forbes Fintech 50 Company. Vir was also listed in the 2018 Medtech Boston Beacon Award Top 50 Companies List, and was recognized as a 2019 Fierce innovation award winner.
References
United States 
